practical immunity

48
Practical Immunity Some diseases and how we are fighting them.

Upload: jesse-bush

Post on 31-Dec-2015

32 views

Category:

Documents


1 download

DESCRIPTION

Practical Immunity. Some diseases and how we are fighting them. Principal Vaccines Used in the United States to Prevent Bacterial Diseases in Humans. DtaP Diphtheria: Purified diphtheria toxoid Pertussis: Acellular fragments of B. pertussis Tetanus: Purified tetanus toxoid - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Practical Immunity

Practical Immunity

Some diseases and how we are fighting them.

Page 2: Practical Immunity

• DtaP– Diphtheria: Purified diphtheria toxoid– Pertussis: Acellular fragments of B. pertussis– Tetanus: Purified tetanus toxoid

• Meningococcal meningitis: Purified polysaccharide from N. meningitidis

• Haemophilus influenzae type b meningitis: Polysaccharides conjugated with protein

• Pneumococcal conjugate vaccine: S. pneumoniae antigens conjugated with protein

Principal Vaccines Used in the United States to Prevent Bacterial

Diseases in Humans

Page 3: Practical Immunity

• Smallpox: Live vaccinia virus• Poliomyelitis: Inactivated virus• Rabies: Inactivated virus• Hepatitis A: Inactivated virus• Influenza: Inactivated or attenuated virus• Measles: Attenuated virus• Mumps: Attenuated virus• Rubella: Attenuated virus• Chickenpox: Attenuated virus• Hepatitis B: Antigenic fragments (recombinant

vaccine)

Principal Vaccines Used in the United States to Prevent Viral Diseases in Humans

Page 4: Practical Immunity

Enzyme-Linked Immunosorbent Assay

(Direct ELISA)

Figure 18.12a

Page 5: Practical Immunity

Enzyme-Linked Immunosorbent Assay

(Indirect ELISA)

Figure 18.12b

Page 6: Practical Immunity

Serological Tests

Figure 18.13

Page 7: Practical Immunity

We will look at a number of things and how they deal with our

immunity.

• Malaria

• HIV

• HepB a subunit vaccine.

• Tissue Transplant

• Asthma

• Leishmaniasis

• Botfly Larvae: MYIASIS

Page 8: Practical Immunity

Malaria

• Kills 1-3 million people a year.

• Hundreds of millions of clinical infections

• Mostly in sub-Saharan Africa

• Anopheles control is the major way.

• What happens if we loose this control?

• In 1985 the mortality rate for Malaria increased to almost 15% from 5% of hospitalized cases in Zaire

Page 9: Practical Immunity

The Biology of Malaria

Page 10: Practical Immunity
Page 11: Practical Immunity

Outline of Infection.

• Organism: Apicomplexan genus of Plasmodium

1. Infective stage is sporozoite moves from mosquito to human blood.

2. Carried to liver, move into cells change to merozoites that move into blood stream and become merozoites (form ring structure in RBC, how can be identified)

Page 12: Practical Immunity

• Cyclically rupture RBC’s and release more infective particles as well as waste products that cause fever.

• Merozoites change into gametocytes where they can be picked up by Mosquitoes.

• Gametocytes unite in the mosquito and can produce sporozoites.

Page 13: Practical Immunity
Page 14: Practical Immunity

• Why do these species usually rupture and cause fever in 24 hr cycles???

• Why are humans considered an intermediate host?

Page 15: Practical Immunity

Problems with Vaccination

• Many diseases do not occur in the US for 1999– 0 rabies– 8 plague– 58 botulism– 0 Yellow fever– 0 small pox

• Is the risk and the expense worth the effort?

Page 16: Practical Immunity

Why does the US not Vaccinate for TB, if a vaccine exists?

• Risk

• Variable result

• Interferes with testing

Page 17: Practical Immunity

What are we trying to induce with vaccination?

• Herd immunity

Page 18: Practical Immunity

Recent studies

• 1993 Childhood Immunization Initiative (CII) increase coverage levels to 90%.

• 1997 best year with 78% 1 million children under the age of 2 still have not received immunizations.

• Other countries?– Measles still accounts for 10% mortality

among children aged less than 5 years

Page 19: Practical Immunity

Why does the rest of the world not have the same vaccination rate as

we do?• Record keeping

• Cannot afford even minimal treatments

• Immunocompramized

• No refrigeration

• No system of distribution

• No profit for drug companies……….

Page 20: Practical Immunity

Do you think that Malaria can be cured by only one type of vaccine?

• No

• We are in the process of developing different antigens that will lead to protective immunity at each state

Page 21: Practical Immunity

• Vaccine against the sporozoites must produce antibodies that work within 30 minutes to block invasion of hepatocites.

• CD4 and CD8 cells must be trained to kill cells with the intrahepatic parasites

• A vaccine against merozoites will block the cyclical invasion of RBC’s

• Antibodies must be created against the malaria toxins to reduce the cyclical fever cause by the release of merozoites

Page 22: Practical Immunity

• Antibodies to parasite antigens expressed on RBC’s block adherence to endothelium and rupturing.

• Cell mediated immunity can be stimulated to kills RBC’s containing the parasite.

• Antibodies to gametocytes can block structures involved in fertilization which would prevent zygote formation in the mosquito.

Page 23: Practical Immunity

Is a malarial Vaccine possible?

Page 24: Practical Immunity

Humoral response to vaccination

Page 25: Practical Immunity
Page 26: Practical Immunity
Page 27: Practical Immunity
Page 28: Practical Immunity

Cell mediated response.

Page 29: Practical Immunity
Page 30: Practical Immunity

HIV

• Lentivirus (retrovirus)

• Genome is RNA

• Particle contains the Enzyme Reverse transcriptase

• Envelope of cytoplasm has viral protein gp120 and others

Page 31: Practical Immunity
Page 32: Practical Immunity

• Spikes allow virus to attaches to CD4 receptor on host cells.

• Receptor is found on Helper T cells, Macrophages and dendritic cells

• Following attachment is absorption and infection

• Infection can be latent or active

Page 33: Practical Immunity
Page 34: Practical Immunity

Stages of HIV infection

• Clinical stages includeCategory A. AsymptomaticCategory B. persistent infections of Candida

albicans denote early indication of immune failure infections that one does not normally get but one gets over it.

Category C. C.a. of esophagus and lung other more serious infections typical AIDS indicator condition. CD4 Tcells>200/mm3

Page 35: Practical Immunity
Page 36: Practical Immunity

HIV vaccine

• Probably most realistic way to control epidemic

• Problems because we lack an animal test model. How do we know this works?

• Rapid mutation rate of GP120 makes it difficult to target.

• Why does HIV have a rapid mutation rate?

Page 37: Practical Immunity

Tissue Transplants

• symptoms

• Biology

• problems

Page 38: Practical Immunity

Asthma

• Symptoms.

• Biology

• Problems

Page 39: Practical Immunity

Leishmaniasis

• 20 different forms of protozoan pathogens.

• Transmitted by bite of female sand flies found in the tropics and deserts.

• Unaffected reservoir of small mammals

• Promastigote in salvia of insect from vector

• Amastigote in phagocyticic cells to vector

Page 40: Practical Immunity

treatments

• 4 weeks of toxic metal antimony

• Amphotericin B

• Fluconazole

Page 41: Practical Immunity

Look at the change of Promastigote to Amastigote

Page 42: Practical Immunity
Page 43: Practical Immunity

Is a vaccine worth making?

• Cost to US?

• Cost world wide.

• Current treatment is toxic.

• How Could we go about making a vaccine?

• Would it necessarily work?

Page 44: Practical Immunity

One method

• Rather than target the pathogen, scientists at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) use fly slava.

• Isolated saliva protein 15 and cloned the gene.

• Made a DNA vaccine

• Provided some protection

• Is this T cell or antibody mediated?

Page 45: Practical Immunity

• Used antibody knock out mice and found that the method still worked.

• Is a T cell mediated response.

Page 46: Practical Immunity

MYIASISIs this a problem?

How is damage done?

Page 47: Practical Immunity
Page 48: Practical Immunity

Practical vaccination

• Making product that will produce an immune response.

• Administering product

• Making sure that product is effective and has low side effects.